Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 12/20 | 0.45 |
| ▸ | ATR | Q13535 | 9/20 | 0.45 |
| ▸ | ATRIP | Q8WXE1 | 9/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25080251 | 0.96 | MTOR (0.46) | MTORATRATRIPHRH3LCK | |
| SCHEMBL25080224 | 0.85 | MTOR (0.48) | MTORATRATRIPLCKNUAK1 | |
| SCHEMBL25080297 | 0.82 | MTOR (0.45) | MTORATRATRIPLCKNUAK1 | |
| SCHEMBL25080574 | 0.81 | HRH3 (0.47) | MTORATRATRIPHRH3 | |
| SCHEMBL25080340 | 0.81 | ATR (0.64) | MTORATRATRIPLCKNUAK1 | |
| SCHEMBL25080698 | 0.80 | ATR (0.68) | MTORATRATRIPLCKNUAK1 | |
| SCHEMBL25080690 | 0.80 | ATR (0.68) | MTORATRATRIPLCKNUAK1 | |
| SCHEMBL25080655 | 0.80 | MTOR (0.42) | MTORATRATRIPHRH3LCK | |
| SCHEMBL25080710 | 0.79 | HRH3 (0.45) | MTORATRATRIPHRH3LCK | |
| SCHEMBL25080796 | 0.79 | HRH3 (0.45) | MTORATRATRIPHRH3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023020604-A1 | FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLIC AND HETEROARYL DERIVATIVE AND USE THEREOF | 南京大美生物制药有限公司 | 2023-02-23 | — | — | WO | disclosed |